Elimination pathways of systemically delivered siRNA

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 381-385

  Huang, Yuanyu ^a   Hong, Junmei ^a   Zheng, Shuquan ^b   Ding, Yi ^a   Guo, Shutao ^c,d   Zhang, Hongyan ^b   Zhang, Xiuqin ^a   Du, Quan ^a   Liang, Zicai ^a  

^a PEKING UNIVERSITY   (China)

^b Suzhou Ribo Life Science Co Ltd   (China)

^c NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^d TIANJIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CHLORAMPHENICOL; CHOLESTEROL; DIGITOXIN; FLUORESCENT DYE; NAKED DNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; GALLBLADDER; HEPATOBILIARY SYSTEM; IN VIVO STUDY; INFRARED RADIATION; INTESTINE; LIGHT SCATTERING; LIVER; MALE; MOUSE; NONHUMAN; PROTEIN SECRETION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 79551617515     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.266     Document Type: Article

References (11)

1. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
2. Bartlett, DW, Su, H, Hildebrandt, IJ, Weber, WA and Davis, ME (2007). Impact of tumorspecific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104: 15549-15554.
3. Jacque, JM, Triques, K and Stevenson, M (2002). Modulation of HIV-1 replication by RNA interference. Nature 418: 435-438.
4. Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007.
5. Ptasznik, A, Nakata, Y, Kalota, A, Emerson, SG and Gewirtz, AM (2004). Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10: 1187-1189.
6. Kim, SH, Jeong, JH, Lee, SH, Kim, SW and Park, TG (2006). PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 116: 123-129.
7. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
8. Hong, J, Huang, Y, Li, J, Yi, F, Zheng, J, Huang, H et al. (2010). Comprehensive analysis of sequence-specific stability of siRNA. FASEB J (epub ahead of print).
9. Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157.
10. Liu, N, Ding, H, Vanderheyden, JL, Zhu, Z and Zhang, Y (2007). Radiolabeling small RNA with technetium-99m for visualizing cellular delivery and mouse biodistribution. Nucl Med Biol 34: 399-404.
11. Lendvai, G, Velikyan, I, Bergström, M, Estrada, S, Laryea, D, Välilä, M et al. (2005). Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci 26: 26-38.